P2 - Topical tactics to limit HIV/HSV spread by mucosal DCs
P2 - 限制粘膜 DC 传播 HIV/HSV 的局部策略
基本信息
- 批准号:7929654
- 负责人:
- 金额:$ 34.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AnimalsBindingBiological AssayCarrageenanCellsChemicalsChlamydiaClinicalCommunitiesDendritic CellsDevelopmentDrug FormulationsDrug KineticsEffectivenessGenerationsGoalsHIVHIV InfectionsHepatitis B VirusHumanHuman Herpesvirus 2Immunologic Deficiency SyndromesIn VitroInfectionInfection preventionMacacaMethodsMonitorMononuclearNatural ImmunityNucleotidesReverse Transcriptase InhibitorsSystemTestingTissuesToxic effectTrichomonasVaginaVirusWorkbaseimprovedin vivomicrobicidenovelpathogenpreclinical studypreventprogramsresearch study
项目摘要
DESCRIPTION (provided by applicant): The aim of this integrated Program is to develop and assay a novel broad-spectrum combination microbicide, ZCM. ZCM comprises Zn bound to carrageenan and the non-nucleotide reverse transcriptase inhibitor MIV-150. We rationalize that preventing pathogen attachment to target cells via carrageenan, combined with the anti-HIV/STI effects of Zn and MIV150, will render this combined formulation highly effective at limiting HIV infection and STIs. Project 1 (Maguire, Project Leader {PL}) focuses on optimizing the development and testing of ZCM formulations, to identify the strongest, most stable and safe ZCM for the studies proposed in Projects 2 and 3. Experiments will involve assaying;formulations containing different concentrations of the 3 components. Stability will be assessed by standard physical and chemical methods. In vitro and FDA-required animal assays will be employed to assay toxicity and animal systems will be used for preliminary pharmacokinetic studies. The major goal of Project 2 (Pope, PL) is to test ZCM for its ability to prevent vaginal infection with immunodeficiency viruses in healthy and HSV-2-infected macaques. Since dendritic cells (DCs) likely drive the early amplification of virus in the tissues and this may be exacerbated by pathogens like HSV-2, DC-based in vitro studies will be performed in parallel to the in vivo work. We will monitor how effective ZCM is at preventing DC-driven infections, while uncovering information about the ability of ZCM to trigger innate immunity that together would contribute to the microbicide actions in vivo. Proposal 3 (Phillips, PL) involves assaying ZCM for effectiveness in preventing infection of primary isolates of HIV in primary human mononuclear cells. In addition, work will focus on developing systems for assaying microbicides against hepatitis B virus (HBV), HSV-2, Chlamydia, and Trichomonas, important STIs that have been relatively understudied by the microbicide community. ZCM will be tested in these new and improved systems for (in vitro and in vivo) efficacy in blocking these important STIs. The ultimate goal of this integrated multi-project pre-clinical study is to develop a new generation carrageenan-based microbicide, ZCM, which will be highly effective against all clinical isolates of HIV and have robust activity in preventing infection by a broad spectrum of STIs.
描述(由申请人提供):该集成程序的目的是开发和测定一种新颖的广谱组合菌心ZCM。 ZCM包括与角叉菜胶和非核苷酸逆转录酶抑制剂MIV-150结合的Zn。我们合理地认为,通过角叉菜胶与Zn和MIV150的抗HIV/STI效应相结合,可以防止病原体附着于靶细胞上,这将使这种合并的配方在限制HIV感染和性传播感染方面非常有效。项目1(Maguire,项目负责人{PL})着重于优化ZCM公式的开发和测试,以确定项目2和3中提出的研究最强,最稳定和最安全的ZCM。实验将涉及分析;包含三个组成部分的不同浓度。稳定性将通过标准的物理和化学方法评估。体外和FDA需要的动物测定将用于测定毒性,动物系统将用于初步的药代动力学研究。项目2(POPE,PL)的主要目标是测试ZCM在健康和HSV-2感染的猕猴中预防具有免疫缺陷病毒的阴道感染的能力。由于树突状细胞(DC)可能会驱动组织中病毒的早期扩增,因此,基于HSV-2(基于DC)的病原体可能会与体外工作同时进行。我们将监视ZCM在防止DC驱动的感染方面的有效性,同时发现有关ZCM触发先天免疫能力的信息,这些信息将共同促进体内杀生性杀菌剂的作用。提案3(Phillips,PL)涉及分析ZCM,以防止原代人单核细胞感染HIV的原发性分离株。此外,工作将集中于开发用于针对丙型肝炎病毒(HBV),HSV-2,衣原体和毛毛虫的系统,这些系统已被微生物群体相对研究。 ZCM将在这些新的和改进的系统中测试(体外和体内)阻断这些重要性传播感染的功效。这项集成的多项目临床前研究的最终目的是开发新一代的基于角叉菜胶的菌心ZCM,它将对所有HIV的所有临床分离株非常有效,并具有强大的活性,以防止广泛的ETIS感染。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Melissa J Robbiani其他文献
Melissa J Robbiani的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Melissa J Robbiani', 18)}}的其他基金
A novel vaginal ring to prevent HIV and HSV-2 infection, as well as pregnancy
一种预防 HIV 和 HSV-2 感染以及怀孕的新型阴道环
- 批准号:
8450072 - 财政年份:2012
- 资助金额:
$ 34.8万 - 项目类别:
A novel vaginal ring to prevent HIV and HSV-2 infection, as well as pregnancy
一种预防 HIV 和 HSV-2 感染以及怀孕的新型阴道环
- 批准号:
8264696 - 财政年份:2012
- 资助金额:
$ 34.8万 - 项目类别:
HIV ENVELOPE SPECIFIC DARPIN-BASED MICROBICIDE
HIV 包膜特异性 DARPIN 杀菌剂
- 批准号:
8358133 - 财政年份:2011
- 资助金额:
$ 34.8万 - 项目类别:
ZCM:A NOVEL BROAD-SPECTRUM MICROBICIDE FOR SEXUALLY TRANSMITTED INFECTIONS
ZCM:一种治疗性传播感染的新型广谱杀菌剂
- 批准号:
8358089 - 财政年份:2011
- 资助金额:
$ 34.8万 - 项目类别:
DENDRITIC CELL ACTIVATION BY ISS ODN FOR SIV IMMUNITY
ISS ODN 激活树突状细胞以增强 SIV 免疫能力
- 批准号:
8358061 - 财政年份:2011
- 资助金额:
$ 34.8万 - 项目类别:
THE MUCOSAL DENDRITIC CELL-T CELL MILIEU AND SIV SPREAD
粘膜树突状细胞 T 细胞环境和 SIV 传播
- 批准号:
8358075 - 财政年份:2011
- 资助金额:
$ 34.8万 - 项目类别:
BLOCKING VIRUS SPREAD BY DCS WITH CARRAGEENAN-BASED COMPOUNDS
用卡拉胶基化合物阻断 DCS 传播的病毒
- 批准号:
8358043 - 财政年份:2011
- 资助金额:
$ 34.8万 - 项目类别:
HIV ENVELOPE SPECIFIC DARPIN-BASED MICROBICIDE
HIV 包膜特异性 DARPIN 杀菌剂
- 批准号:
8173046 - 财政年份:2010
- 资助金额:
$ 34.8万 - 项目类别:
ZCM:A NOVEL BROAD-SPECTRUM MICROBICIDE FOR SEXUALLY TRANSMITTED INFECTIONS
ZCM:一种治疗性传播感染的新型广谱杀菌剂
- 批准号:
8172989 - 财政年份:2010
- 资助金额:
$ 34.8万 - 项目类别:
相似国自然基金
结合态抗生素在水产品加工过程中的消解机制与产物毒性解析
- 批准号:32302247
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ABHD6与AMPA受体结合位点的鉴定及该位点在AMPA受体转运和功能调控中的作用研究
- 批准号:32300794
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
α-突触核蛋白与脂肪酸结合蛋白FABP3相互作用维持自身低聚体形态的机制研究
- 批准号:82301632
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于荧光共振能量转移机理构建多肽荧光探针用于可视化Zn2+结合SQSTM1/p62调节自噬在前列腺癌去势耐受中的作用机制
- 批准号:82303568
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
手性氢键供体与阴离子结合催化乙烯基醚的立体选择性阳离子聚合
- 批准号:22301279
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Anti-Complement Immunotherapy for Pancreatic Cancer
胰腺癌的抗补体免疫治疗
- 批准号:
10751872 - 财政年份:2024
- 资助金额:
$ 34.8万 - 项目类别:
Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies
基于同种异体 BAFF 配体的 CAR T 细胞作为 B 细胞恶性肿瘤的新疗法
- 批准号:
10698759 - 财政年份:2023
- 资助金额:
$ 34.8万 - 项目类别:
Targeting Myosin to Treat Polycystic Kidney Disease
靶向肌球蛋白治疗多囊肾
- 批准号:
10699859 - 财政年份:2023
- 资助金额:
$ 34.8万 - 项目类别:
DRUG DISCOVERY BY DIRECTED EVOLUTION IN MAMMALIAN CELLS
通过哺乳动物细胞定向进化发现药物
- 批准号:
10644749 - 财政年份:2023
- 资助金额:
$ 34.8万 - 项目类别:
Molecular Mechanisms of TRIB1 Regulation of Hepatic Metabolism
TRIB1调节肝脏代谢的分子机制
- 批准号:
10660520 - 财政年份:2023
- 资助金额:
$ 34.8万 - 项目类别: